Karim Fizazi, MD, PhD, of the University Paris-Sud, discusses study findings on androgen-deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer. (Abstract LBA3)
Julie Vose, MD, MBA, of the University of Nebraska Medical Center, discusses two hematologic abstracts: results from the OPTIMAL>60 study on radiotherapy to bulky disease PET-negative after immunochemotherapy in elderly patients with diffuse large B-cell lymphoma; and an analysis of autologous vs matched sibling donor or matched unrelated donor allogeneic hematopoietic cell transplantation in follicular lymphoma patients with early chemoimmunotherapy failure. (Abstracts 7506, 7508)
Temidayo Fadelu, MD, of Dana-Farber Cancer Institute, discusses study findings on nut consumption and survival in stage III colon cancer patients. Higher consumption of nuts may be associated with significantly reduced cancer recurrence and death in this group. (Abstract 3517)
Solange Peters, MD, PhD, of the University of Lausanne, examines the study findings on nivolumab ± ipilimumab in advanced small cell lung cancer, in the first report of a randomized expansion cohort. (Abstract 8503)
Nicholas D. James, MBBS, PhD, of Queen Elizabeth Hospital, discusses study findings on adding abiraterone for men with high-risk prostate cancer starting long-term androgen-deprivation therapy (Abstract LBA5003).
Jame Abraham, MD, of the Cleveland Clinic, gives his views on findings on abemaciclib in combination with fulvestrant in patients with HR+/HER2- advanced breast cancer who progressed on endocrine therapy. (Abstract 1000)
